Desvenlafaxine

Desvenlafaxine
Skeletal formula
Ball-and-stick model of desvenlafaxine
Clinical data
Pronunciation/dɛsˌvɛnləˈfæksiːn/
des-ven-lə-FAK-seen
Trade namesPristiq, Desfax, Ellefore, others
Other namesO-desmethylvenlafaxine, WY-45233
AHFS/Drugs.comMonograph
MedlinePlusa608022
License data
Pregnancy
category
  • AU: B2
Routes of
administration
By mouth
Drug classSerotonin–norepinephrine reuptake inhibitor (SNRI)
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability80%
Protein bindingLow (30%)
MetabolismCYP2C19, CYP3A4, (CYP2D6 is not involved)
Elimination half-life11 hours
Excretion45% excreted unchanged in urine
Identifiers
  • (RS)-4-[2-dimethylamino-1-(1-hydroxycyclohexyl)
    ethyl]phenol
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.149.615
Chemical and physical data
FormulaC16H25NO2
Molar mass263.381 g·mol−1
3D model (JSmol)
  • OC2(C(c1ccc(O)cc1)CN(C)C)CCCCC2
  • InChI=1S/C16H25NO2/c1-17(2)12-15(13-6-8-14(18)9-7-13)16(19)10-4-3-5-11-16/h6-9,15,18-19H,3-5,10-12H2,1-2H3 checkY
  • Key:KYYIDSXMWOZKMP-UHFFFAOYSA-N checkY
 X markNcheckY (what is this?)  (verify)

Desvenlafaxine, sold under the brand name Pristiq among others, is a medication used to treat major depressive disorder. It is an antidepressant of the serotonin–norepinephrine reuptake inhibitor (SNRI) class and is taken by mouth. It is recommended that the need for further treatment be occasionally reassessed. Studies have shown similar effectiveness compared to its parent compound venlafaxine.

Common side effects include dizziness, trouble sleeping, increased sweating, constipation, sleepiness, anxiety, and sexual problems. In some patients, sexual dysfunction may persist even after the drug is discontinued, a condition known as post-SSRI sexual dysfunction; regulatory agencies including the European Medicines Agency and Health Canada have recommended that desvenlafaxine's product labeling warn of this risk. Serious side effects may include suicide in those under the age of 25, serotonin syndrome, bleeding, mania, and high blood pressure.

Desvenlafaxine was approved for medical use in the United States in 2008. In Europe its application for use was denied in 2009, although has since been approved for Spain and Germany. In 2023, it was the 189th most commonly prescribed medication in the United States, with more than 2 million prescriptions.